What is ArunA Bio?
Headquartered in Athens, Georgia, ArunA Bio operates at the intersection of biotechnology and neuro-regenerative research. Since its inception in 2003, the company has pioneered the use of neural exosomes as a vehicle to cross the blood-brain barrier, a critical hurdle in treating central nervous system disorders. Their research portfolio spans drug toxicity assays and the development of therapeutic agents designed to stimulate the body's innate anti-inflammatory and self-repair mechanisms. By focusing on the natural biological properties of exosomes, ArunA Bio provides a scalable solution for delivering payloads directly to the brain, positioning itself as a high-value asset in the global biotech landscape.
How much funding has ArunA Bio raised?
ArunA Bio has raised a total of $20.2M across 4 funding rounds:
Private Equity
$3.7M
Unspecified
$5.3M
Debt
$350K
Other Financing Round
$10.8M
Private Equity (2016): $3.7M, investors not publicly disclosed
Unspecified (2018): $5.3M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Other Financing Round (2021): $10.8M, investors not publicly disclosed
Key Investors in ArunA Bio
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for ArunA Bio?
With this recent infusion of capital, ArunA Bio is well-positioned to accelerate its clinical development pipeline and expand its manufacturing capabilities for exosome-based therapeutics. The company is expected to prioritize the validation of its delivery platform in human trials, aiming to address unmet needs in neurodegenerative diseases. As the firm transitions into a more mature enterprise-level phase, strategic partnerships with pharmaceutical giants will likely be the next catalyst for growth, enabling the commercialization of its proprietary technology on a global scale.
See full ArunA Bio company page
